These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 19767063

  • 1. Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
    Jewell EL, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA, Berchuck A, Secord AA.
    Gynecol Oncol; 2009 Dec; 115(3):424-9. PubMed ID: 19767063
    [Abstract] [Full Text] [Related]

  • 2. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Secord AA, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA, Berchuck A, Gynecologic Oncology Group study.
    Gynecol Oncol; 2007 Jul; 106(1):221-32. PubMed ID: 17481705
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
    Alvarez AA, Axelrod JR, Whitaker RS, Isner PD, Bentley RC, Dodge RK, Rodriguez GC.
    Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
    [Abstract] [Full Text] [Related]

  • 6. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.
    Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnoila RI, Hendricks D, Bonome T, Farley JH, Gynecologic Oncology Group.
    Gynecol Oncol; 2008 Dec; 111(3):487-95. PubMed ID: 18834621
    [Abstract] [Full Text] [Related]

  • 7. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
    Sun LX, Wu Y, Han HQ, Wang QH.
    Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
    Rubatt JM, Darcy KM, Hutson A, Bean SM, Havrilesky LJ, Grace LA, Berchuck A, Secord AA.
    Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
    [Abstract] [Full Text] [Related]

  • 11. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer.
    Seo SS, Song YS, Kang DH, Park IA, Bang YJ, Kang SB, Lee HP.
    Gynecol Oncol; 2004 Mar; 92(3):927-35. PubMed ID: 14984962
    [Abstract] [Full Text] [Related]

  • 12. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
    Chen YJ, Yuan CC, Chow KC, Wang PH, Lai CR, Yen MS, Wang LS.
    Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
    Bagnoli M, Ambrogi F, Pilotti S, Alberti P, Ditto A, Barbareschi M, Galligioni E, Biganzoli E, Canevari S, Mezzanzanica D.
    Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
    [Abstract] [Full Text] [Related]

  • 15. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
    Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC.
    J Clin Oncol; 2008 Jul 10; 26(20):3418-25. PubMed ID: 18612157
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
    Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC.
    Gynecol Oncol; 2008 Jan 10; 108(1):100-5. PubMed ID: 17920108
    [Abstract] [Full Text] [Related]

  • 18. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer.
    Solomon LA, Munkarah AR, Schimp VL, Arabi MH, Morris RT, Nassar H, Ali-Fehmi R.
    Gynecol Oncol; 2006 Jun 10; 101(3):385-9. PubMed ID: 16443262
    [Abstract] [Full Text] [Related]

  • 19. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
    Bolat F, Gumurdulu D, Erkanli S, Kayaselcuk F, Zeren H, Ali Vardar M, Kuscu E.
    Pathol Res Pract; 2008 Jun 10; 204(6):379-87. PubMed ID: 18343598
    [Abstract] [Full Text] [Related]

  • 20. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients.
    Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Barnes MN.
    Gynecol Oncol; 2008 Feb 10; 108(2):336-41. PubMed ID: 18006047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.